Welcome to our dedicated page for Ambrx Biopharma news (Ticker: AMAM), a resource for investors and traders seeking the latest updates and insights on Ambrx Biopharma stock.
Ambrx Biopharma Inc. (NASDAQ: AMAM) is a clinical-stage biotechnology pioneer developing precision antibody-drug conjugates (ADCs) for oncology through its proprietary protein engineering platform. This page serves as the definitive source for AMAM news, providing investors and researchers with timely updates on clinical developments, corporate milestones, and therapeutic innovations.
Access consolidated updates on AMAM's ADC pipeline progress, including Phase 1/2 trials for ARX517 (PSMA-targeting prostate cancer therapy) and ARX788 (HER2-positive cancer treatment). Track strategic partnerships, regulatory filings, and financial disclosures that impact the company's trajectory in the competitive biopharma sector.
Our news collection features verified press releases on clinical trial results, manufacturing advancements, and intellectual property developments. Stay informed about AMAM's expanded genetic code technology applications and their implications for next-generation cancer therapeutics.
Bookmark this page for streamlined access to material events affecting AMAM's market position. Check regularly for updates on ADC platform innovations, peer-reviewed research publications, and executive leadership announcements from this oncology-focused biotech innovator.
Anebulo Pharmaceuticals (NASDAQ: ANEB) reported financial results for Q2 FY2022, highlighting a net loss of $1.1 million or $(0.05) per share, compared to a loss of $0.3 million or $(0.03) in Q2 FY2021. Operating expenses rose to $1.1 million from $0.3 million year-on-year. The company initiated a Phase 2 study of ANEB-001 for acute cannabinoid intoxication, expects topline results in H1 2022, and discussed clinical development with the FDA. The firm holds $18.0 million in cash as of December 31, 2021, down from $19.9 million in June 2021.
Ambrx Biopharma (NYSE: AMAM) has appointed Paul V. Maier to its Board of Directors and as Chair of the Audit Committee. Maier brings over 25 years of experience in the pharmaceutical and biotechnology sectors, having held senior roles at Sequenom and Ligand Pharmaceuticals. His expertise is expected to enhance Ambrx’s strategic direction and financial oversight as the company advances its pipeline of Engineered Precision Biologics, including antibody drug candidates and novel therapies. This leadership change aims to drive value creation for stakeholders.
Anebulo Pharmaceuticals (NASDAQ: ANEB) has appointed Simon Allen as CEO and a Board member, effective February 1, 2022. He succeeds Daniel Schneeberger, MD, who has resigned. Allen previously served as Chief Business Officer at Ambrx Biopharma (NYSE: AMAM) and brings extensive leadership experience. Anebulo's primary focus is developing ANEB-001, aimed at treating acute cannabinoid intoxication, a growing concern with rising THC concentrations. The company anticipates reporting topline results from its Phase 2 trial in the first half of 2022.
Ambrx Biopharma (NYSE: AMAM) announced successful Phase 1 trial results of ARX788 at the San Antonio Breast Cancer Symposium, demonstrating a 100% disease control rate in 29 patients. These patients had previously undergone a median of seven anti-HER2 therapies. The study reported a confirmed objective response rate of 66% in trastuzumab regimens and 80% in HER2 ADC regimens. ARX788 showed low systemic toxicity and was well tolerated. Ambrx is also advancing its Phase 2 trial, ACE-Breast-03, to further evaluate ARX788's efficacy in resistant HER2-positive metastatic breast cancer.
Ambrx Biopharma (NYSE: AMAM) announced its participation in the 2021 San Antonio Breast Cancer Symposium, featuring clinical data from its ACE-Breast-01 and ACE-Breast-03 trials of ARX788. The ACE-Breast-01 trial abstract received a Spotlight Poster Discussion designation, highlighting its significance. Presentations will take place from December 7-10, 2021, with the ACE-Breast-01 spotlight discussion scheduled for December 9 at 7:00 AM CST. Ambrx focuses on developing Engineered Precision Biologics using expanded genetic code technology.
Ambrx Biopharma Inc. (NYSE: AMAM) has initiated the first patient dosing in its global ACE-Breast-03 Phase 2 clinical study of ARX788, targeting HER2-positive metastatic breast cancer. This study evaluates ARX788's efficacy in patients resistant to existing therapies. The drug received Fast-Track Designation from the FDA in December 2020. CEO Feng Tian highlighted recent progress in clinical trials and the positive data seen in ARX788 for gastric cancer, supported by capital raised from their June 2021 IPO, positioning Ambrx for several near-term milestones.
Ambrx Biopharma Inc. (NYSE: AMAM) announced that CEO Feng Tian will present at the 30th Annual Virtual Credit Suisse Healthcare Conference on November 8, 2021, at 4:20 PM ET. The presentation will be accessible via a live webcast on the company's website, and a replay will be available for 90 days afterward. Ambrx focuses on Engineered Precision Biologics through an expanded genetic code platform, aiming to develop innovative therapies, including antibody drug conjugates and targeted immuno-oncology treatments.
Ambrx Biopharma Inc. (NYSE: AMAM) reported its financial results for the first half of 2021, showing a revenue decline to $5.1 million from $6.5 million in the same period last year. The company announced significant clinical developments, including the dosing of the first patient in the ACE-Gastric-02 Phase 2/3 study and positive interim data for ARX788 presented at CSCO. R&D expenses surged to $22.1 million, largely due to new clinical trial costs. Ambrx ended the period with $167.2 million in cash, following a successful IPO that raised $126 million.
Ambrx (AMAM) announced positive interim data from the ACE-Gastric-01 Phase 1 study of ARX788 for HER2+ gastric cancer, revealing an overall response rate (ORR) of 44.4%. The study, conducted in China, involved 30 patients with low rates of drug-related severe adverse events (6.7%). Median overall survival (mOS) was 10.7 months, while enrollment in the study is now complete. Additionally, the first patient was dosed in the ACE-Gastric-02 global Phase 2/3 trial, further advancing the collaboration with NovoCodex.
Ambrx (NYSE: AMAM) announced participation of CEO Feng Tian, Ph.D., in a virtual panel at the H.C. Wainwright 23rd Annual Global Investment Conference on September 14, 2021, at 1:30 pm EDT. The topic will focus on engineered cytokines in immune-oncology, addressing their potential as a revolutionary treatment.
The session, led by Michael King, will explore innovative approaches within Ambrx's portfolio, including their lead candidate ARX788. Interested individuals can access the discussion via the company's website.
